This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
BRD7 · Western blot design guide
BRD7 Western Blot Planning Guide
Plan a BRD7 Western blot around the catalog-observed 74.1 kDa band, image-backed A01289-1 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
BRD7 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 74.1 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Breast | |
| Negative control | Soft tissue |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 74.1 kDa |
| ⓘ | Localization | Nucleus / Chromosome |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated BRD7 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Adrenal gland |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A01289-1 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected BRD7 Western Blot Band Size?
Use the product-observed 74.1 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 74.1 kDa | Matches the authoritative product WB observation. |
| 74.1 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected BRD7 appearancePlan around 74.1 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 74.1 kDa; use this as the primary experimental expectation. |
| Calculated mass | 74.1 kDa from UniProt Q9NPI1; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A01289-1. |
| Situation | Likely cause | Next action |
|---|---|---|
| 74.1 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing BRD7 band
A01289-1 · BRD7
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for BRD7 Western blot
🧪Use Breast as the first positive-control candidate and Soft tissue as the HPA Not detected negative candidate.
Positive control: Breast (High)
Negative control: Soft tissue (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for BRD7
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Breast | Reported tissue cells | High | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | High | Protein (HPA) | HPA → |
| Appendix | Reported tissue cells | High | Protein (HPA) | HPA → |
| Bone marrow | Reported tissue cells | High | Protein (HPA) | HPA → |
Section 3
Advanced BRD7 Western Blot Tips
Deeper troubleshooting and optimisation questions for BRD7, answered from its protein features.
Which band should guide the blot?
Use 74.1 kDa, the observation attached to the authoritative A01289-1 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 74.1 kDa expectation.
Which positive control should I start with?
Start with Breast, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Soft tissue as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for BRD7 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A01289-1 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
BRD7 Western Blot Reagents
Human/Mouse/Rat-reactive BRD7 Western blot reagents with authoritative product imagery.
Real WB data
Anti-BRD7 Antibody Picoband®
Cat # A01289-1
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q9NPI1
- Human Protein Atlas — BRD7
- A01289-1 product record
- PMC8965117 — BRD7 Stabilizes P53 via Dephosphorylation of MDM2 to Inhibit Tumor Growth in Breast Cancer Harboring Wild-type P53 (Journal of Cancer, 2022)
- PMC8181413 — BRD7 Promotes Cell Proliferation and Tumor Growth Through Stabilization of c-Myc in Colorectal Cancer (Frontiers in cell and developmental biology, 2021)
- PMC4079724 — BRD7 regulates XBP1s' activity and glucose homeostasis through its interaction with the regulatory subunits of PI3K (Cell metabolism, 2014)